• PDHA1 Acetylation, Cuproptosis, and Enzalutamide Resistance

  2026-09-19

  This study identifies PDHA1 acetylation signaling as a metabolic–epigenetic axis that suppresses cuproptosis and weakens enzalutamide activity in castration-resistant prostate cancer. Its findings connect acetyl-CoA production, H3K27ac, SLC7A11-driven glutathione synthesis, and copper handling, suggesting that PDHA1 targeting may help restore anti-androgen sensitivity in resistant disease.

• Mitoxantrone: Mechanism, Resistance & Research Use

  2026-09-18

  Mitoxantrone is a topoisomerase II inhibitor and anticancer research compound that damages DNA through intercalation and stabilization of the DNA–topoisomerase II complex. Mitozantrone is a spelling variant used in some searches; this article uses the standard name, Mitoxantrone, and explains ABCG2-mediated resistance, product handling, and assay integration.

• IWP-2 Wnt Production Inhibitor Workflow

  2026-09-17

  Build reproducible Wnt pathway experiments with IWP-2 by pairing Porcupine inhibition with orthogonal transcriptional, phenotypic, and apoptosis readouts. The workflow separates literature-backed product performance from practical optimization, helping researchers move from gastric cancer models to carefully bounded cross-domain assay design.

• GDC-0068 (RG7440) Pan-AKT Inhibitor

  2026-09-17

  GDC-0068, also known as RG7440, is an ATP-competitive pan-AKT inhibitor that targets Akt1, Akt2, and Akt3. Product information supports its use as a research tool for studying PI3K/Akt/mTOR signaling, cell-cycle control, and preclinical tumor models, especially those with PTEN loss or PI3K pathway activation.

• HO-1, ROS, and HBV Replication: ICAA Study

  2026-09-16

  A recent Antiviral Research study shows that isochlorogenic acid A suppresses HBV at multiple stages, including transcription, genome production, cccDNA maintenance, capsid formation, and envelopment. Its mechanistic contribution is the connection of these antiviral effects with HO-1 upregulation and altered intracellular ROS, while also identifying viral protein thiol chemistry as a possible link to defective morphogenesis.

• Nitrocefin Workflows for β-Lactamase Assays

  2026-09-16

  Nitrocefin converts β-lactamase hydrolysis into a visible and spectrophotometric signal, making it useful for resistance profiling, mechanistic enzyme studies, and inhibitor screening. This workflow-focused guide connects assay setup and troubleshooting with the 2024 structure-guided peptide discovery study targeting TEM-1 β-lactamase.

• Tin Mesoporphyrin IX: HO Assay Workflows

  2026-09-15

  A practical guide to using Tin Mesoporphyrin IX (chloride) as a direct pharmacological probe of heme oxygenase activity. The workflow connects enzyme inhibition with metabolic, ROS, and HBV-related assays while emphasizing controls, dose selection, and troubleshooting.

• D-Lin-MC3-DMA: From LNP Design to Assays

  2026-09-15

  Dlin-MC3-DMA is an ionizable cationic liposome lipid for siRNA and mRNA delivery. This article explains how its chemistry, formulation variables, and machine-learning evidence can guide more informative LNP assay decisions.

• TAK-242: A Translational Lens on TLR4 Biology

  2026-09-14

  TAK-242 (Resatorvid) offers translational researchers a selective way to interrogate TLR4 signaling, connect LPS-driven inflammation with neuroimmune outcomes, and distinguish receptor-proximal biology from downstream inflammatory effects. This thought-leadership guide integrates mechanistic rationale, evidence from an aged-rat cognitive model, practical protocol design, and strategic considerations for advancing neuroinflammation research.

• Z-VAD-FMK in Resistant Lung Cancer Assays

  2026-09-14

  Z-VAD-FMK enables causal testing of caspase dependence in drug-resistant lung cancer models. This guide connects apoptosis inhibition with ferroptosis-aware assay design and insights from a 2025 EGFR-mutant lung adenocarcinoma study.

• Cabazitaxel Workflow for Resistant Tumor Models

  2026-09-13

  Cabazitaxel (XRP6258, SKU B2157) provides a practical antiproliferative agent in cancer research focused on microtubule dynamics disruption, including taxane-resistant and P-glycoprotein-expressing models. It is intended for DMSO- or ethanol-based workflows, not direct aqueous preparation, and prepared solutions should be used promptly rather than stored long term.

• Bestatin as a Chemical Genetics Tool for Jasmonate Signaling

  2026-09-12

  Zheng and colleagues showed that the aminopeptidase inhibitor bestatin can selectively activate jasmonate responses in tomato and Arabidopsis, while using its root-growth phenotype to isolate bestatin-resistant mutants. The study established a chemical-genetics framework that links pharmacological perturbation, transcriptomics, developmental phenotyping, and mutant analysis to identify previously unrecognized components of jasmonate signaling.

• Dlin-MC3-DMA for LNP RNA Delivery

  2026-09-12

  Dlin-MC3-DMA supports high-potency siRNA and mRNA nanoparticle workflows, from hepatic gene silencing to cell-state-sensitive microglia assays. This practical guide connects formulation design, machine-learning-assisted screening, and troubleshooting for more reproducible RNA delivery experiments.

• Fluorouracil and Wnt: A Translational Playbook

  2026-09-11

  Fluorouracil is more than a viability benchmark. This thought-leadership guide connects its thymidylate synthase mechanism with Wnt-driven tumor biology, immune context, experimental design, and translational decision-making in solid tumor research.

• Nuclear mTORC1 Control Revealed by TerminaTOR

  2026-09-11

  The reference study introduces TerminaTOR, a genetically encodable inhibitor that can suppress mTORC1 selectively at defined subcellular locations. By separating lysosomal from nuclear mTORC1 activity, the authors show that nuclear mTORC1 regulates transcription of genes containing CCAAT motifs, extending mTORC1 biology beyond its canonical metabolic and translational functions.

8733 records 3/583 page Previous Next 12345 下5页 Last page